Resources

This tool is designed to help global health stakeholders, procurers, and advocates estimate the annual operating expenditures (OPEX) of pressure swing adsorption (PSA) oxygen plants in low- and middle-income countries (LMICs). It is intended to support advocacy, planning, and comparative analysis related to oxygen system investments.The tool generates approximate operating cost estimates based on key PSA plant specifications and operating assumptions. Users should complete all input fields to the best of their ability using information available for the plant being assessed. Suggested values are provided for selected inputs to support users when site-specific information is unavailable.The estimates produced by this tool are intended to provide a standardized, evidence-informed basis for discussion and comparison across settings. The tool is not intended to serve as a detailed budgeting, procurement, or financial planning tool.

This is a simple, Excel-based tool for assessing and comparing costs of respiratory syncytial virus (RSV) intervention programs annually and for a period of five years with RSV maternal vaccine and monoclonal antibody (mAb) products available in the global market.It aims to help country-level policymakers compare products and estimate intervention program costs for both RSV maternal vaccine and mAbs. The tool can be used by decision-makers, implementers, technical partners, and others in any country, whether or not the country is eligible for co-funding from Gavi, the Vaccine Alliance.Product cost estimates (i.e., supplies procurement and international shipping) and immunization program costs (i.e., cost of delivery) are calculated separately for two perspectives: (1) the country perspective and (2) the combined country and donor/Gavi perspective (only relevant for Gavi-eligible countries). The tool also calculates the estimated cold chain volume requirements, which can support operational planning and logistics.It's important to note that cost is only one consideration when selecting an RSV intervention product, and users involved in decision-making around new vaccine introduction or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. The tool is available to download in multiple languages below. For questions or support, contact PATH’s Health Economics & Outcomes Research Team: HEOR@path.org.

This document highlights the potential of intradermal vaccine delivery to improve vaccine equity through dose sparing, simplified administration, and expanded access. Learn about emerging ID injection technologies such as: autodisable ID needle and syringe, disposable-syringe jet injectors, and syringe-based hollow microneedle devices. Includes an overview of PATH’s work to assess the value, feasibility, and adoption of these innovations in low- and middle-income countries.

The Financial Advisory Strategy Taskforce (FAST), led by PATH with support from Coefficient Giving and GiveWell, is a multi-country initiative to provide targeted technical assistance to ministries of health to respond to funding disruptions. The program aims to equip countries with data-driven insights to optimize existing funding and commodity flows for maximum impact, along with providing strategic planning tools and technical support to respond to the acute funding crisis.This fact sheet describes the FAST initiative in the Democratic Republic of the Congo (DRC), where it supports the Ministry of Health in responding to funding reductions through evidence-based planning and strategic resource allocation. It highlights the project's key priority areas, core objectives, and major achievements to date.Learn more about FAST here.

The Financial Advisory Strategy Taskforce (FAST), led by PATH with support from Coefficient Giving and GiveWell, is a multi-country initiative to provide targeted technical assistance to ministries of health to respond to funding disruptions. The program aims to equip countries with data-driven insights to optimize existing funding and commodity flows for maximum impact, along with providing strategic planning tools and technical support to respond to the acute funding crisis.This fact sheet describes the FAST initiative in Mozambique, where it supports the Ministry of Health in responding to funding reductions through evidence-based planning and strategic resource allocation. It highlights the project's key priority areas, core objectives, and major achievements to date.Available in English and Portuguese.Learn more about FAST here.